Researchers: IRA May Disrupt Development Of Non-Opioid Pain Meds

A controversial provision under Medicare’s new drug price negotiation program that permits Medicare to negotiate lower prices for small-molecule drugs after nine years on the market could throw off existing efforts to curb an ongoing epidemic of opioid overdoses in the United States by disincentivizing the development of non-opioid pain medications, most of which are small molecule drugs, according to a new policy paper by the Pioneer Institute. In the paper published by the nonpartisan, fiscally conservative think tank ,...